Electrical deep brain stimulation (DBS) of the subthalamic nucleus (STN) is effective for ameliorating the motor symptoms of Parkinson's disease (PD) including bradykinesia. The STN receives its main excitatory input from cortex; however, the contribution of cortico-subthalamic projection neurons to the effects of DBS remains unclear. To isolate the consequences of stimulating layer 5 primary motor cortex (M1) projections to the STN, we used a dual virus transfection technique to selectively express opsins in these neurons in mice made parkinsonian by unilateral nigrostriatal 6-OHDA lesioning. AAVs containing WGA-Cre constructs were injected in the STN to retrogradely place Cre in STN afferents, while AAVs containing Cre-dependent ultrafast hChR2(E123T/T159C)-EYFP opsin constructs were injected in M1 layer 5, producing specific opsin expression in M1-STN projections. Under unstimulated conditions, lesioned mice showed bradykinesia and hypokinesia (decreased movement), along with electrophysiological changes similar to those observed in PD patients. Specifically, low frequency power (theta, alpha, low beta) was increased and gamma power was decreased, while M1/STN coherence and STN phase-amplitude-coupling (PAC) were increased. Optogenetic stimulation (100-130 Hz) of STN afferents in these mice ameliorated bradykinesia and hypokinesia and brought the neural dynamics closer to the non-parkinsonian state by reducing theta and alpha and increasing gamma power in M1, decreasing STN PAC, and reducing theta band coherence. Histological examination of the EYFP expression revealed that, in addition to orthodromic and antidromic effects, stimulation of cortico-subthalamic neurons may cause wide-spread increased glutamatergic activity due to collaterals that project to areas of the thalamus and other brain regions.
Introduction
Treatment with the dopamine precursor L-DOPA can ameliorate bradykinesia (abnormal slowing of movement) in most Parkinson's disease (PD) patients for 10 years or more. However, many patients eventually require supplemental treatments due to the progressive nature of the disease and the dyskinesias (involuntary movements) that often occur after prolonged L-DOPA use. Deep brain stimulation (DBS) of the STN has been shown to be an effective treatment for bradykinesia in humans (Benabid et al., 2009; DeLong and Wichmann, 2007; Wichmann and DeLong, 2011) , and rats (Li et al., 2012) , and can prolong the effective window of L-DOPA therapy. However, optimizing DBS treatment to subject-specific neural dysfunction and symptom profiles is often difficult due to a lack of understanding about the cellular and circuit activations (and/or deactivations) that lead to the DBS therapeutic effects. Previous studies have shown evidence that activation of layer 5 cortico-subthalamic projections and antidromic effects may play an important role in the DBS therapeutic mechanism (Gradinaru et al., 2009; Li et al., 2007) . Additionally, recent discoveries about the role of STN in motor behavior have emphasized the importance of the STN in movement stopping and initiation. For example, STN activation in inhibiting ongoing movements has been demonstrated (Chu et al., 2015; Mallet et al., 2016) , and increased STN neuron spiking has been observed immediately subsequent to stop cues and contralateral movement initiation cues (Schmidt et al., 2013) .
Previously, Gradinaru et al., 2009 found that high frequency optogenetic stimulation of cortico-subthalamic projections ameliorated ipsilateral rotations in mice unilaterally lesioned with 6-OHDA. However, these initial studies were performed in Thy1::ChR2 line 18 transgenic mice that expressed first generation ChR2 opsins in many locations including layer 5 cortical neurons across the entire cortex, CA1 and CA3 pyramidal neurons of the hippocampus, and neurons in the thalamus (Arenkiel et al., 2007) . The slower response kinetics of the ChR2 opsin and the broad expression of ChR2 under control of the Thy1 promoter led to concerns regarding the specificity and mechanism of action involved in the 2009 results. Motivated in part by these concerns, the study reported here examined whether specific optogenetic stimulation of second-generation ultrafast opsins [hChR2(E123T/T159C)] placed Neurobiology of Disease 95 (2016) [225] [226] [227] [228] [229] [230] [231] [232] [233] [234] [235] [236] [237] 
